Brought to you by 
Ensemble helps Roche create personalized cancer medicines
03 Mar 2011
Executive Summary
In its first alliance, Ensemble Discovery (chemistry, biology, and nanotechnology drug discovery tools) has agreed to use its DNA-Programmed Chemistry platform to produce a molecular diagnostic that will help Roche identify patients most likely to gain benefits from anti-epidermal growth factor receptor (EGFR) drugs.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ensemble helps Roche create personalized cancer medicines
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice